首页>Leukemia and lymphoma>Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia
Final safety and efficacy results from the CPX-351 early access program for older patients with high-risk or secondary acute myeloid leukemia
作者单位:Franciscan Hlth, Indianapolis, IN USA[1]Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA[2]Weill Cornell Med, New York, NY USA[3]Univ Kansas, Med Ctr, Kansas City, KS 66103 USA[4]Northside Hosp Canc Ctr Inst, Leukemia Program, Atlanta, GA USA[5]Jazz Pharmaceut, Palo Alto, CA USA[6]Rush Univ, Med Ctr, Chicago, IL 60612 USA[7]